Cyclic amp-specific pdes: A promising therapeutic target for cns repair

Translational Neuroscience

Volumn 1, Issue 2, 2010, Pages 101-105

  Ghosh, Mousumi ^a   Pearse, Damien D ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

CNS repair; Cyclic AMP; Phosphodiesterase; Rolipram; SCI; TBI

Indexed keywords

CYCLIC AMP PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ARTHRITIS; ARTICLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; NAUSEA; NERVE REGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; STOMACH DISEASE; VOMITING;

EID: 79952341193     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/v10134-010-0012-0     Document Type: Article

References (56)

1. E.W. Sutherland and T.W. Rall, JAm Chem Soc., 1957, 79:3608.
2. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007, 76:481-511.
3. Cooper DM. Compartmentalization of adenylate cyclase and cAMP signalling. Biochem Soc Trans. Dec; 2005, 33 (Pt 6):1319-22. (Pubitemid 41779677)
4. Willoughby D, Wong W, Schaack J, Scott JD, Cooper DM. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J. 2006, 25(10):2051-61.
5. Houslay MD. PDE4 cAMP-specific phosphodiesterases Prog Nucleic Acid Res Mol Biol.; 2001, 69:249-315. (Pubitemid 33805840)
6. Ian McPhee, Susan Cochrana and Miles D. Houslay. The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. Cell. Signal. 2001, 13, 911-918
7. Cherry, J.A. and Davis, R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 1999, 407, 287-301 (Pubitemid 29162777)
8. Engels, P. et al. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J. Neurosci. Res. 1995, 41, 169-178
9. Bos, J. L. EPAC: A new cAMP target and new avenues in cAMP research. Nature Rev. Mol. Cell Biol. 2003, 4, 733-738 (Pubitemid 37082188)
10. Sasaki, T., Kotera, J. & Omori, K. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem. J. 2002, 361, 211-220 (Pubitemid 34174488)
11. Reyes-Irisarri, E., Perez, S. & Mengod, G. Neuronal expression of cAMPspecific phosphodiesterase 7B in the rat brain. Neuroscience 2005, 132, 1173-1185 (Pubitemid 40602550)
12. Pérez-Torres S, Cortés R, Tolnay M, Probst A, Palacios JM, Mengod G. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol. 2003, 182(2):322-34 (Pubitemid 36937085)
13. Miro, X., Perez-Torres, S., Palacios, J. M., Puigdomenech, P. & Mengod, G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 201-214.
14. Donnelly DJ, Popovich PG 2008, Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 209:378-388. (Pubitemid 351181428)
15. Dhillon HS, Yang L, Padmaperuma B, Dempsey RJ, Fiscus RR, Renuka Prasad M. Regional concentrations of cyclic nucleotides after experimental brain injury. J Neurotrauma, 1995, 12(6):1035-43. (Pubitemid 26044667)
16. Atkins CM, Oliva AA Jr, Alonso OF, Pearse DD, Bramlett HM, Dietrich WD Modulation of the cAMP signaling pathway after traumatic brain injury. Exp Neurol. 2007, 208(1):145-58. (Pubitemid 47600157)
17. Pearse DD, Pereira FC, Marcillo AE, Bates ML, Berrocal YA, Filbin MT, Bunge MB. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med. 2004, 10(6):610-6. (Pubitemid 38796852)
18. Ghavami A, Hirst WD, Novak TJ. Selective phosphodiesterase (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs R D. 2006, 7(2):63-71.
19. Whitaker CM, Beaumont E, Wells MJ, Magnuson DS, Hetman M, Onifer SM. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci Lett.. 2008 20;438(2):200-4.
20. Hannila SS, Filbin MT. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol. 2008, 209(2):321-32. (Pubitemid 351174133)
21. Ariga, M. et al. Non-redundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 2004, 173, 7531-7538 (Pubitemid 39628194)
22. Dusart I and Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci.; 1994, 6:712-724. (Pubitemid 24143919)
23. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol. 1997; 377:443-464. (Pubitemid 27016650)
24. Carlson SL, Parrish ME, Springer JE, Acute inflammatory response in spinal cord following impact injury. Exp Neurol.; 1998, 151:77-88. (Pubitemid 28223857)
25. Parkes, J.D. et al. Rolipram in Parkinson's disease. Adv. Neurol. 1984, 40, 563-565
26. Barad, M., Bourtchouladze, R., Winder, D. G., Golan, D. G. & Kandel, E. R. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl Acad. Sci. USA. 1998, 95,15020-15025. (Pubitemid 29003749)
27. Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A 2004, 8; 101(23):8786-90. (Pubitemid 38745849)
28. O'Donnell, J.M. and Zhang, H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 2004, 25, 158-163. (Pubitemid 38264507)
29. Frank S. Menniti, W. Stephen Faraci and Christopher J. Schmidt. Phosphodiesterases in the CNS:targets for drug development. Nature, 2006, 660, 5.
30. Hwang TL, Zhuo SK, Pan YL. YC-1 attenuates homotypic human neutrophil aggregation through inhibition of phosphodiesterase activity. Eur J Pharmacol.2008, 28; 579(1-3):395-402.
31. Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM, Carmo AF, Russo RC, Garcia CC, Bonjardim CA, Alessandri AL, Rossi AG, Pinho V, Teixeira MM. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-{kappa}B-independent manner. J Leukoc Biol. 2010, Jan 26 issue.
32. Schaal SM, Garg MS, Golshani R, et al. Targeting phosphodiesterase-4 after spinal cord injury using pharmacological and molecular approaches Conference Information: 26th Annual National- Neurotrauma-Society Symposium, 2008, JUL 27-30, 2008 Orlando, FL JOURNAL OF NEUROTRAUMA Volume: 25 Issue: 7 Pages: 927- 927 Meeting Abstract: P297
33. Feng Bao, PhD; Marta Markowski; Roozbeh Roozbeh Golshani; Damien D Pearse,Levent Kasabov; Jennifer C Fleming,; Arthur Brown; Lynne C Weaver, A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes and tissue damage after spinal cord injuryExperimental Neurology, 2010, under review.
34. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol. 1997; 377:443-464. (Pubitemid 27016650)
35. Beaumont E, Whitaker CM, Burke DA, Hetman M, Onifer SM. Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury. Neuroscience. 2009, 163(4):985-90.
36. Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci Lett. 2007, 418(2):165-9. (Pubitemid 46636000)
37. Cai D, Deng K, Mellado W, Lee J, Ratan RR, Filbin MT. Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron. 2002; 35(4):711-9.
38. Murray AJ, Tucker SJ, Shewan DA. cAMP-dependent axon guidance is distinctly regulated by Epac and protein kinase A. J Neurosci. 2009; 29(49):15434-44.
39. Gao Y, Nikulina E, Mellado W, Filbin MT. Neurotrophins elevate cAMP to reach a threshold required to overcome inhibition by MAG through extracellular signal-regulated kinase-dependent inhibition of phosphodiesterase. J Neurosci. 2003,23(37):11770-7. (Pubitemid 38021304)
40. Miles D.Houslay,Peter Schafer and Kam Y.J.Zhang Phosphodiesterase-4 as atherapeutic target. DDT 2005, 10, 22.
41. Koopmans GC, Deumens R, Buss A, Geoghegan L, Myint AM, Honig WH, Kern N, Joosten EA, Noth J, Brook GA. Acute rolipram/ thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury. Exp Neurol. 2009.
42. DeMarch Z, Giampà C, Patassini S, Bernardi G, Fusco FR. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis. Jun; 2008, 30(3):375-87.
43. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest. 2004, 114(11):1624-34. (Pubitemid 40385553)
44. Casacchia M, Meco G, Castellana F, Bedini L, Cusimano G, Agnoli A. Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease. Pharmacol Res Commun. 1983, 15(3):329-34. (Pubitemid 13122657)
45. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol. 2002; 135(1):113-8. (Pubitemid 34102104)
46. Lerner, A. and Epstein, P. M. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem. J. 2006, 393, 21-41. (Pubitemid 43049299)
47. Huang, Z. and Mancini, J. A. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr. Med. Chem. 2006, 13, 3253-3262.
48. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, Liu S, Huang Z, Conti M, Chan CC. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptormediated anesthesia, a behavioral correlate of emesis. J Clin Invest. Oct; 2002, 110(7):1045-52.
49. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: Guarded optimism or wishful thinking? Br J Pharmacol. 2008, 155(3):288-90. Epub 2008 Jul 28.
50. Pagès L, Gavaldà A, Lehner MD. PDE4 inhibitors: A review of current developments (2005 - 2009). Expert Opin Ther Pat. 2009, 19(11):1501-19.
51. Jin, S.L. and Conti, M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 7628-7633. (Pubitemid 34568742)
52. Jin, S.L. et al. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4Ddeficient mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 11998-12003. (Pubitemid 29502847)
53. Mehats, C., Jin, S.-L. C, Wahlstrom, J., Law, E., Umetsu, D, T., AND Conti, M. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J. 2003, 17,1831-1841. (Pubitemid 37214777)
54. Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. 2009, Curr Pharm Des.; 15(14):1688-98.
55. Fortin M, D'Anjou H, Higgins ME, Gougeon J, Aubé P, Moktefi K, Mouissi S, Séguin S, Séguin R, Renzi PM, Paquet L, Ferrari N. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir Res. 2009, 20; 10:39.
56. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal. 2005, 17(9):1158-73. (Pubitemid 40933535)